Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma
Yunzhan Li, Hanif Khan, Şeyma Demirsoy, Muhammad Younis et autres
Glioblastoma (GBM) is the most aggressive primary brain tumor with limited therapeutic options and extremely poor prognosis. Aberrant activation of the receptor tyrosine kinase MET drives tumor progression, therapeutic resistance, and reduced survival, particularly in the mesenchymal GBM subtype. Given its crucial …
cn, us (code pays fourni par la source)
0 citations
International Journal of Molecular Sciences